Erasca, Inc. (ERAS)
Develops cancer drugs targeting RAS mutations that drive tumor growth.
$18.05-0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+1198.6%
The outlook
ERAS is trading at $18.05 with analyst consensus leaning toward Buy, and the stock sits comfortably above both its 50- and 200-day moving averages. The average analyst price target sits roughly 26% above the current price, while the stock trades about three-quarters of the way up its 52-week range.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 10 analysts
Price trendAbove its 50- & 200-day averages
52-week range73% of the way from its 52-week low to high
Price targetAvg target +26% vs current price
Analyst price target
~12-month · 10 analysts$22.80average target+26.3% vs now
Now $18.05
Low $18.00High $30.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$6.27B
52-wk high
$24.28
52-wk low
$1.33
50-day avg
$15.36
200-day avg
$10.59
Trailing P/E
—